[ad_1]
Melbourne researchers led by Monash University have obtained advanced evidence to support the development of a new class of drugs to modulate blood pressure and age-related changes in cardiovascular function. It is widely recognized that inflammation plays a central role in the development and progression of several chronic cardiovascular diseases and accounts for 40 percent of all deaths in elderly patients. But scientists still don’t fully understand how ongoing inflammation in midlife can worsen heart health as we age. A team of researchers led by the Monash Institute for Pharmaceutical Sciences (MIPS), in collaboration with the Baker Heart and Diabetes Institute, has investigated how the naturally occurring protein Annexin A1 (ANXA1) potentially protects against infections. I set out on a mission to find out if it was possible. The negative effects of aging on blood pressure and cardiovascular health. Lead author Chengxue Helena Qin, Ph.D., director of the MIPS laboratory and National Heart Foundation Future Fellow, said the role of naturally occurring resolution-promoting mediators, such as ANXA1, in slowing the progression of age-related cardiovascular disease has been extensively studied. He said that he had not done so. . “Our preclinical studies in mice concluded that ANXA1 may play an important role in regulating blood pressure, controlling heart function, and even preventing the worsening of heart disease,” said Dr. Qin. said.
“Studies revealed that middle-aged mice lacking ANXA1 experienced more inflammation and damage in their hearts and blood vessels. “This study shows that blood pressure may play a role in causing heart and blood vessel problems. This could open up new possibilities for treating high blood pressure and reducing age-related heart problems.” It may be preventable. Professor Owen Woodman, co-senior author from MIPS’ Heart Failure Pharmacology Laboratory and Cardiovascular Pharmacology Laboratory, said: “This study shows that unresolved inflammation contributes to age-related cardiovascular dysfunction.” “This suggests potential and therefore may offer new therapeutic opportunities to regulate blood.” Reduces pressure and prevents age-related cardiovascular diseases. ”
Lead author Jaydeep Singh, a PhD candidate at MIPS, said previous attempts to treat cardiovascular disease by suppressing inflammation had limited success.
“Rather than tackling inflammation after cardiovascular disease has already occurred, we believe that a more productive approach is to address inflammation as a natural way to prevent or reverse cardiovascular disease progression. We have a hypothesis,” Singh said. “So we turned to ANXA1, which has the ability to heal inflammation in a natural way.”
“Overall, our data reveal compelling new insights into the potential for developing ANXA1-nature methods to treat cardiovascular disease, especially in an aging population.”
The study was published in the Journal of the Federation of American Societies for Experimental Biology and received funding from the National Heart Foundation.
Click here to read the full study.
https://doi.org/10.1096/fj.202301802R
/Open to the public. This material from the original organization/author may be of a contemporary nature and has been edited for clarity, style, and length. Mirage.News does not take any institutional position or stance, and all views, positions, and conclusions expressed herein are solely those of the authors.
[ad_2]
Source link